Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

Recruiting now · Phase 4

Conditions studied: Thrombocytopenia

In brief

This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery

Key facts

Study ID

NCT06562738

Run by

The Third People's Hospital of Chengdu

People needed

55

Starts

2024-06-01

Expected to finish

2025-03-31

Last updated by the study team

2024-08-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old; diagnosis of immune thrombocytopenia.
• Platelets ≤75×10\^9/L before scheduled elective surgery.

You may not qualify if…

• History of allergy to Thrombopoietin Receptor Agonists (TPO-RA) drugs;
• Severe bleeding symptoms, such as gastrointestinal bleeding, bleeding of important organs, and intracranial bleeding;
• Thrombotic diseases, such as pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation (DIC);
• Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody;
• New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure;
• History of angina pectoris, myocardial infarction or cerebral infarction within 6 months before the screening period;
• Have an active infection that is difficult to control;
• Pregnant or lactating women;
• Other conditions determined by the investigator to be unsuitable for inclusion in the study

Where it is running

• Chengdu Third People's Hospital — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.